Introduction
A malar rash, commonly known as a butterfly rash due to its distinctive shape, is a facial erythema across the cheeks and nasal bridge, typically sparing the nasolabial folds. This dermatological presentation is a frequent sign of various underlying conditions, both systemic and localized. The rash can be transient or persistent and may extend to other areas of the face. Accurate differential diagnosis of a butterfly rash is crucial as it can be indicative of conditions ranging from dermatological infections to systemic autoimmune diseases like systemic lupus erythematosus (SLE). This article aims to provide a detailed overview of the Butterfly Rash Differential Diagnosis, assisting healthcare professionals in effective evaluation and management.
The butterfly rash is notably associated with systemic lupus erythematosus and is recognized as one of the diagnostic criteria by the American College of Rheumatology for SLE. It can also manifest in other forms of lupus, including discoid lupus and subacute cutaneous lupus. However, it is essential to consider a broad spectrum of differential diagnoses, including rosacea, cellulitis, erysipelas, dermatomyositis, and pellagra, to ensure accurate diagnosis and appropriate treatment. The initial management of a butterfly rash involves sun protection and subsequently, addressing the underlying cause.
Etiology of Butterfly Rash
The appearance of a butterfly rash can be attributed to a diverse range of systemic and local diseases. Recognizing the potential etiologies is the first step in formulating a comprehensive differential diagnosis.
Common causes of a butterfly rash include:
- Erysipelas
- Cellulitis
- Systemic Lupus Erythematosus (SLE)
- Rosacea
- Pellagra
- Dermatomyositis
Erysipelas
Erysipelas is a superficial bacterial skin infection primarily affecting the upper dermis and superficial lymphatics. Characteristically, it presents as a painful, rapidly progressing, well-defined, erythematous, and shiny plaque. Perifollicular edema and peau d’orange (orange peel appearance) are also typical findings. Patients often exhibit acute systemic symptoms such as fever, chills, and malaise. Distinguishing erysipelas from other causes of butterfly rash is crucial due to its infectious etiology requiring prompt antibiotic treatment.
Cellulitis
Cellulitis is another bacterial skin infection, but it involves the deeper dermis and subcutaneous fat. Unlike erysipelas, cellulitis is typically less demarcated, with minimal edema, and systemic symptoms are less common or more indolent. While cellulitis can present on the face, it is important to differentiate it from erysipelas and other conditions in the butterfly rash differential diagnosis due to variations in clinical presentation and management approaches.
Systemic Lupus Erythematosus (SLE)
Systemic lupus erythematosus is a chronic autoimmune disease that can affect multiple organ systems. In SLE, the immune system produces autoantibodies that can target various tissues and organs, including the skin, joints, kidneys, brain, and heart. The severity of SLE can range from mild rashes and arthritis to severe organ damage and life-threatening complications. The butterfly rash of SLE is a hallmark cutaneous manifestation, often photosensitive, and can be a crucial diagnostic clue, especially when accompanied by other systemic symptoms.
Rosacea
Rosacea is a chronic inflammatory skin condition predominantly affecting the central face, particularly in middle-aged individuals with fair skin. It is considered the most common cause of malar rash. Rosacea is characterized by erythema, telangiectasia, papules, and pustules, but typically lacks comedones. Flushing episodes triggered by factors like hot drinks, stress, or alcohol are common in rosacea. While rosacea can mimic a butterfly rash, it is distinct from SLE and other causes in its pathogenesis and lack of systemic involvement.
Pellagra
Pellagra is a systemic disease resulting from niacin (vitamin B3) deficiency. It is classically described by the “4 D’s”: dermatitis, diarrhea, dementia, and death. The dermatitis of pellagra is a photosensitive, bilaterally symmetrical rash that appears in sun-exposed areas. In its acute phase, the skin lesions can be painful. Pellagra, although less common in developed countries, should be considered in the differential diagnosis of butterfly rash, especially in patients with nutritional deficiencies or malabsorption issues.
Dermatomyositis
Dermatomyositis (DM) is an idiopathic inflammatory myopathy that can affect individuals of all ages. DM is associated with various skin manifestations, including poikiloderma, which is characterized by hyperpigmentation, hypopigmentation, epidermal atrophy, and telangiectasias. Poikiloderma in DM often has a characteristic distribution on sun-exposed areas, including the face, eyelids, elbows, knees, knuckles, chest, and back. The facial rash in dermatomyositis may resemble a butterfly rash but is often more violaceous in color compared to the erythema seen in SLE.
Epidemiology of Conditions Presenting with Butterfly Rash
Understanding the epidemiology of conditions associated with butterfly rash is essential for assessing patient risk and prioritizing differential diagnoses.
Cellulitis and Erysipelas
Cellulitis and erysipelas are common infections affecting diverse populations. Precise prevalence data is challenging to obtain as these conditions are not always reported systematically. They occur across all racial and ethnic groups, highlighting the broad population at risk.
Rosacea
Rosacea is a prevalent chronic inflammatory facial disorder with a global prevalence estimated at 5.46%. Individuals with fair skin, particularly those with skin phototypes I and II, are at a higher risk. In fair-skinned populations, the prevalence of rosacea ranges from 2% to 22%, emphasizing its significant occurrence in certain demographics.
Systemic Lupus Erythematosus (SLE)
The Lupus Foundation of America estimates that at least 1.5 million individuals in the United States have lupus. Global prevalence and incidence studies of SLE indicate the highest rates in North America (prevalence: 241/100,000; incidence: 23.2/100,000 person-years). Lower incidence rates are reported in regions like Ukraine and Africa (0.3/100,000 person-years). SLE disproportionately affects women across all age and ethnic groups. Individuals of African ethnicity have the highest prevalence and incidence, while those of White race have the lowest. The annual incidence of SLE has been estimated to range from 1 to 10 per 100,000 population, and prevalence from 5.8 to 130 per 100,000 population, illustrating the variability across geographic regions and populations.
Pellagra
Pellagra epidemics are no longer prevalent in the United States, but sporadic cases still occur. Risk groups include individuals with malabsorption disorders, alcoholism, illegal drug dependence, and those following fad diets that lead to nutritional deficiencies. While rare in developed countries, pellagra remains a relevant differential diagnosis in specific patient populations.
Dermatomyositis
The estimated incidence of dermatomyositis is 9.63 cases per million population. DM exhibits a bimodal age distribution, with incidence peaks at 5 to 15 years and 45 to 60 years. This bimodal distribution is important to consider when evaluating the likelihood of dermatomyositis in patients presenting with a butterfly rash at different ages.
Histopathology in Butterfly Rash Differential Diagnosis
Histopathological examination can provide valuable insights in differentiating the causes of a butterfly rash, especially when clinical presentation is ambiguous.
Cellulitis
Histopathology of cellulitis reveals dilated dermal and subepidermal vessels and lymphatics with marked edema. A dense and diffuse neutrophil infiltration is typically observed beneath the edema. These findings are consistent with an acute bacterial infection.
Erysipelas
Histopathological evaluation of erysipelas demonstrates significant dermal edema, vascular dilatation, and bacterial invasion into lymphatics and connective tissue. Blood vessel invasion is less common. These features are similar to cellulitis but often more superficial and sharply demarcated.
Dermatomyositis and SLE
The histopathological findings in dermatomyositis and SLE share some similarities, including epidermal thinning, basal layer hydropic degeneration, disrupted dermo-epidermal junction, upper dermal edema, and sparse lymphocytic infiltration. Connective tissue fibrinoid degeneration may also be present. A key differentiating factor is direct immunofluorescence microscopy. In SLE, deposition of immunoglobulin G (IgG), immunoglobulin M (IgM), and C3 is detected at the basement membrane in both lesional and non-lesional skin. This finding is not typical in dermatomyositis, aiding in the differentiation between these two conditions.
Rosacea
Histopathology of rosacea reveals dilated vessels, lymphohistiocytic infiltration around hair follicles and blood vessels, neutrophils within hair follicles, and edema. Sebaceous gland hyperplasia, connective tissue expansion, and elastosis can also be observed. These findings reflect the chronic inflammatory nature of rosacea.
Pellagra
Microscopic findings in pellagra are often non-specific and can resemble other nutritional deficiencies. They may include acanthosis, hyperkeratosis, and parakeratosis. Psoriasiform hyperplasia, ballooning keratinocytes, increased melanin in the upper epidermis, perivascular inflammatory infiltrate, and telangiectasia can also be present. Due to the non-specificity, histopathology alone is rarely diagnostic for pellagra but can support clinical suspicion.
History and Physical Examination in Butterfly Rash Evaluation
A thorough history and physical examination are paramount in the differential diagnosis of a butterfly rash. Given the broad spectrum of potential underlying conditions, a detailed clinical assessment is essential.
A comprehensive evaluation should include:
- Detailed medical history: Including onset, duration, progression of the rash, associated symptoms (fever, joint pain, fatigue, gastrointestinal issues, neurological symptoms), past medical history, medications, allergies, and family history of autoimmune diseases or skin conditions.
- Physical examination: A complete dermatological examination focusing on the characteristics of the rash (morphology, distribution, color, texture, presence of scales, vesicles, or pustules), as well as a systemic examination to identify any signs of underlying systemic disease. Pay close attention to associated skin findings beyond the face and signs of systemic involvement.
Evaluation Strategies for Butterfly Rash
The evaluation of a butterfly rash is guided by the suspected underlying condition based on history and physical exam findings.
Cellulitis and Erysipelas
Uncomplicated cases of erysipelas and cellulitis typically do not require extensive laboratory workup. However, in patients with systemic toxicity or diagnostic uncertainty, laboratory blood tests, such as complete blood count (CBC) with differential, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP), may be indicated to assess the severity of infection and guide management.
Systemic Lupus Erythematosus (SLE)
A butterfly rash associated with systemic lupus erythematosus may precede other systemic symptoms by months or years or appear concurrently with acute SLE manifestations. Initial laboratory evaluation for suspected SLE-related butterfly rash includes antinuclear antibody (ANA) testing, CRP, and ESR. A skin biopsy for histopathology and direct immunofluorescence can provide further diagnostic support. Positive ANA, elevated inflammatory markers, and characteristic histopathological findings support the diagnosis of SLE.
Dermatomyositis
For patients presenting with a butterfly rash suggestive of dermatomyositis without overt muscle weakness, a skin biopsy is crucial for diagnosis. Patients with skin findings alone (amyopathic dermatomyositis) should be monitored for the development of muscle disease. Regular evaluation, every 2 to 3 months, including serum creatine kinase (CK) and aldolase levels, along with muscle strength examination, is recommended to detect potential muscle involvement.
Rosacea
The diagnosis of rosacea is primarily clinical, based on the characteristic features of the rash, including persistent facial erythema, telangiectasia, papules, and pustules, in the absence of comedones. Laboratory tests and skin biopsies are generally not required for typical rosacea diagnosis.
Pellagra
The diagnosis of pellagra is based on clinical presentation and response to niacin (vitamin B3) supplementation. Laboratory tests can support the diagnosis, including blood count (to assess for anemia), serum protein levels (for hypoproteinemia), phosphorus, calcium, serum niacin, and NAD/NADP levels. Low urinary levels of N-methyl nicotinamide can also be indicative of niacin deficiency.
Treatment and Management of Butterfly Rash
Management of a butterfly rash is directed at treating the underlying cause and alleviating symptoms.
Cellulitis and Erysipelas
The cornerstone of treatment for cellulitis and erysipelas is antibiotic therapy, which can be administered orally or intravenously depending on the severity of the infection. Prompt antibiotic treatment is essential to prevent complications and resolve the infection.
SLE and Dermatomyositis
Initial management for butterfly rash in SLE and dermatomyositis focuses on sun protection, including sunscreens, protective clothing, and behavior modification to minimize sun exposure. Subsequent treatment options include topical or intralesional corticosteroids, antimalarial medications, and immunosuppressive agents, depending on disease severity and systemic involvement.
Rosacea
Treatment for rosacea aims to reduce redness, inflammation, and associated symptoms. Topical therapies, such as gels and creams containing metronidazole, azelaic acid, or ivermectin, are commonly used. Oral antibiotics, like tetracyclines, may be prescribed to control inflammation. Vascular lasers and intense pulsed light (IPL) can be used to treat persistent erythema and telangiectasia.
Pellagra
Pellagra is effectively treated with oral niacin or nicotinamide supplementation. Nutritional support and addressing underlying causes of niacin deficiency are also crucial components of management.
Differential Diagnosis of Butterfly Rash
The differential diagnosis of butterfly rash encompasses a range of conditions, requiring careful clinical evaluation to differentiate between them.
Key differential diagnoses include:
- Cellulitis
- Dermatomyositis
- Erysipelas
- Pellagra
- Rosacea
- Systemic Lupus Erythematosus (SLE)
Prognosis of Butterfly Rash
The prognosis of a butterfly rash is highly dependent on the underlying cause.
- Erysipelas and Cellulitis: Prognosis is generally excellent with timely antibiotic treatment.
- Rosacea: Rosacea is a chronic condition with a variable course, often characterized by relapses and remissions. Long-term management is typically required.
- SLE and Dermatomyositis: Prognosis varies widely depending on disease activity, organ involvement, and response to therapy. These are chronic conditions requiring ongoing management and monitoring.
- Pellagra: Prognosis is excellent with niacin supplementation and correction of nutritional deficiencies.
Consultations for Butterfly Rash
Depending on the suspected underlying condition, consultations with specialists may be appropriate.
Consider consultations with:
- Dermatology: For skin-focused conditions like rosacea, erysipelas, cellulitis, and initial evaluation of undifferentiated rashes.
- Rheumatology: For suspected autoimmune conditions like SLE and dermatomyositis.
- Infectious Disease: For complex or recurrent cases of cellulitis or erysipelas.
Deterrence and Patient Education for Butterfly Rash
Patient education is crucial in managing and deterring conditions associated with butterfly rash.
Key points for patient education include:
- Sun Protection: Emphasize the importance of daily sun protection, especially for conditions like SLE, dermatomyositis, and rosacea, as sun exposure can exacerbate symptoms.
- Adherence to Treatment: Ensure patients understand their treatment plan and the importance of adherence, whether it involves antibiotics for infections, topical or systemic medications for chronic conditions, or nutritional supplements for deficiencies.
- Awareness of Triggers: Educate patients with rosacea about potential triggers, such as hot drinks, alcohol, spicy foods, and stress, and strategies to avoid them.
- Recognizing Symptoms: Instruct patients to recognize early signs of recurrence or worsening of their condition and when to seek medical attention.
Enhancing Healthcare Team Outcomes in Butterfly Rash Management
Effective management of butterfly rash requires a collaborative, interprofessional team approach.
Key strategies to enhance healthcare team outcomes include:
- Interdisciplinary Collaboration: Encourage communication and collaboration between primary care providers, dermatologists, rheumatologists, infectious disease specialists, and other healthcare professionals as needed.
- Comprehensive Assessment: Emphasize the importance of thorough history taking and physical examination by all team members to ensure accurate diagnosis.
- Patient-Centered Care: Focus on providing patient-centered care, incorporating patient preferences and values into the management plan.
- Continuous Education: Promote ongoing education for healthcare team members on the differential diagnosis and management of butterfly rash and associated conditions to optimize patient outcomes.
Review Questions
Figure
Figure 1. Facial Rash: Illustrative example of a butterfly rash on bilateral cheeks, characteristically sparing the nasolabial folds.
Figure
Figure 2. Erysipelas Rash: Clinical presentation of erysipelas, a bacterial skin infection that can mimic a butterfly rash.
Figure
Figure 3. Dermatomyositis Rash: Example of dermatomyositis rash, demonstrating the skin manifestations associated with this inflammatory myopathy.
References
1.Dreizen S. The butterfly rash and the malar flush. What diseases do these signs reflect? Postgrad Med. 1991 Jan;89(1):225-8, 233-4. [PubMed: 1824645]
2.Uva L, Miguel D, Pinheiro C, Freitas JP, Marques Gomes M, Filipe P. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis. 2012;2012:834291. [PMC free article: PMC3410306] [PubMed: 22888407]
3.O’Connor K, Paauw D. Erysipelas: rare but important cause of malar rash. Am J Med. 2010 May;123(5):414-6. [PubMed: 20399315]
4.Celestin R, Brown J, Kihiczak G, Schwartz RA. Erysipelas: a common potentially dangerous infection. Acta Dermatovenerol Alp Pannonica Adriat. 2007 Sep;16(3):123-7. [PubMed: 17994173]
5.Stulberg DL, Penrod MA, Blatny RA. Common bacterial skin infections. Am Fam Physician. 2002 Jul 01;66(1):119-24. [PubMed: 12126026]
6.Askanase A, Shum K, Mitnick H. Systemic lupus erythematosus: an overview. Soc Work Health Care. 2012;51(7):576-86. [PubMed: 22905974]
7.Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician. 2002 Aug 01;66(3):435-40. [PubMed: 12182520]
8.Tyler I, Wiseman MC, Crawford RI, Birmingham CL. Cutaneous manifestations of eating disorders. J Cutan Med Surg. 2002 Jul-Aug;6(4):345-53. [PubMed: 11951131]
9.Karthikeyan K, Thappa DM. Pellagra and skin. Int J Dermatol. 2002 Aug;41(8):476-81. [PubMed: 12207761]
10.Isaac S. The “gauntlet” of pellagra. Int J Dermatol. 1998 Aug;37(8):599. [PubMed: 9732006]
11.Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010 Jan;146(1):26-30. [PMC free article: PMC2886726] [PubMed: 20083689]
12.Strowd LC, Jorizzo JL. Review of dermatomyositis: establishing the diagnosis and treatment algorithm. J Dermatolog Treat. 2013 Dec;24(6):418-21. [PubMed: 22686682]
13.Spoendlin J, Voegel JJ, Jick SS, Meier CR. A study on the epidemiology of rosacea in the U.K. Br J Dermatol. 2012 Sep;167(3):598-605. [PubMed: 22564022]
14.Rainer BM, Fischer AH, Luz Felipe da Silva D, Kang S, Chien AL. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am Acad Dermatol. 2015 Oct;73(4):604-8. [PubMed: 26256428]
15.Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013 Dec;69(6 Suppl 1):S27-35. [PubMed: 24229634]
16.Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017 Nov 01;56(11):1945-1961. [PubMed: 28968809]
17.Lorentzen HF, Fugleholm AM, Weismann K. [Zinc deficiency and pellagra in alcohol abuse]. Ugeskr Laeger. 2000 Dec 11;162(50):6854-6. [PubMed: 11187143]
18.Lu JY, Yu CL, Wu MZ. Pellagra in an immunocompetent patient with cytomegalovirus colitis. Am J Gastroenterol. 2001 Mar;96(3):932-4. [PubMed: 11280594]
19.Kertesz SG. Pellagra in 2 homeless men. Mayo Clin Proc. 2001 Mar;76(3):315-8. [PubMed: 11243279]
20.Drucker AM, Piguet V. Hot Stuff: Thermal Imaging Aids in Cellulitis Diagnosis. J Invest Dermatol. 2018 Mar;138(3):482-484. [PubMed: 29477190]
21.Kazandjieva J, Tsankov N, Pramatarov K. The red face revisited: connective tissue disorders. Clin Dermatol. 2014 Jan-Feb;32(1):153-8. [PubMed: 24314389]
22.Lee WJ, Jung JM, Lee YJ, Won CH, Chang SE, Choi JH, Moon KC, Lee MW. Histopathological Analysis of 226 Patients With Rosacea According to Rosacea Subtype and Severity. Am J Dermatopathol. 2016 May;38(5):347-52. [PubMed: 26460622]
23.Sato M, Matsumura Y, Kojima A, Nakashima C, Katoh M, Kore-Eda S, Miyachi Y. Pellagra-like erythema on sun-exposed skin of patients with anorexia nervosa. J Dermatol. 2011 Oct;38(10):1037-40. [PubMed: 21592198]
